Published: Fri, May 19, 2017
Business | By Max Garcia

Axsome Therapeutics (AXSM) Receives Daily News Sentiment Score of 0.22

The stock has "Buy" rating by Brean Capital on Monday, October 3. BTIG Research's price objective would suggest a potential upside of 268.42% from the company's previous close.

Among 2 analysts covering Midstates Petroleum (NYSE:MPO), 0 have Buy rating, 0 Sell and 2 Hold.

Pain Therapeutics (NASDAQ:PTIE) last announced its earnings results on Tuesday, April 25th. Finally, Aegis reissued a "buy" rating on shares of Axsome Therapeutics in a report on Tuesday, March 21st. Alpha One also assigned news stories about the biopharmaceutical company an impact score of 100 out of 100, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the next few days.

The stock of Axsome Therapeutics Incorporated (NASDAQ:AXSM) registered an increase of 21.8% in short interest. The company's market cap is $27.88 million. Further back, their 200-Day Simple Moving Average is -30.00% difference from today's price. Axsome Therapeutics has a one year low of $3.53 and a one year high of $11.50. Its up 21.8% from 337,100 shares, reported previously. On average, equities research analysts predict that Pain Therapeutics will post $1.29 earnings per share for the current fiscal year. News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics, Inc. with's FREE daily email newsletter. If you are accessing this article on another publication, it was copied illegally and reposted in violation of U.S. and global copyright & trademark laws.

A number of hedge funds have recently added to or reduced their stakes in AXSM. Axsome Therapeutics earned a news sentiment score of 0.22 on AlphaOne's scale. Geode Capital Management LLC boosted its position in shares of Axsome Therapeutics by 9.8% in the first quarter. 197,851 shares of the stock were exchanged. Vanguard Group Inc. now owns 334,745 shares of the company's stock valued at $1,305,000 after buying an additional 62,556 shares in the last quarter. The Firm is engaged in developing therapies for the management of central nervous system disorders, including pain.

Since the beginning of the calendar year, Axsome Therapeutics, Inc. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Like this: